Contact us

Support


Home > Investment tools > They choose Russia > Sun Pharmaceutical Industries

Sun Pharmaceutical Industries

One of the world’s leading generics manufacturers — Indian Sun Pharmaceutical Industries (Sun Pharma) — has announced the purchase of 85.1% of shares of Biosintez making part of Biotech pharmaceutical holding. Biotech representative has confirmed the transaction. The transaction amount accounts for $60 mln, including Russian company’s $36 mln debt assumed by Sun Pharma, according to the information provided by the latter.

24 November 2016
Vedomosti
Investor
60.0 mln
Penza Region

Investor profile

Sun Pharmaceutical Industries

India

Company's website: www.sunpharma.com

T: +91 22 4324 4324

Public Company

E-mail: secretarial@sunpharma.com

Contact: ISRAEL MAKOV, Chairman of Board of Directors

Sun Pharma is the leading Indian pharmaceutical company that has consistently ranked in the global TOP 5 generics manufacturers. Sun Pharma has 47 facilities located on 6 continents, R&D centres distributed around the world, and multi-cultural employees representing more than 50 nationalities. Company’s overall revenue for a 12-month period until March 2016 inclusive accounted for about $4.3 bln, of which the US market share accounts for $2.1 bln. The Company occupies a leading position among 12 categories of Indian physicians representing 32 brands in India’s TOP 300 pharmaceutical brands. The Company is represented in over 100 emerging markets and 6 markets of Western Europe. Company’s business in the OTC segment is in TOP 10 in 4 world markets. Company’s business in the API segment is based on 14 top-class facilities worldwide.

Subscribe to Newsletters

Email: